Metabolic dysfunction-associated steatotic liver disease and risk of four intrahepatic and extrahepatic diseases Yiyuan Xiao, Sihua Xu, Wenyan Hu, Jiapeng Huang, Deke Jiang, Rong Na, Zhaoqing Yin, Jingjing Zhang, Haitao Chen Annals of Hepatology.2025; 30(1): 101750. CrossRef
Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip Clinical and Molecular Hepatology.2025; 31(Suppl): S51. CrossRef
Efficacy of measuring natural killer-activating receptor ligands to predict the pathogenesis of metabolic dysfunction-associated steatotic liver disease Jun Arai, Akinori Okumura, Satoshi Kimoto, Kazumasa Sakamoto, Tomoya Kitada, Rena Kitano, Tadahisa Inoue, Sayaka Nishimura, Noriko Inden, Yukiko Muraki, Naoya Kato, Kiyoaki Ito Hepatology International.2025; 19(4): 836. CrossRef
C-C motif chemokines ligand 7 contributes to metabolic dysfunction-associated steatotic liver disease by enabling redox-sensitive induction of hypermethylated in cancer 1 Xinyue Sun, Jinge Wu, Huiqian Lv, Ben Wang, Xuelian Chen, Wenjing Ren, Xiulian Miao, Yan Guo, Xiaocen Kong, Huihui Xu, Zeqing Bao, Yong Xu, Zilong Li Metabolism.2025; 168: 156242. CrossRef
Association between nonalcholic fatty liver disease and pancreatic cancer: Epidemiology, mechanisms, and antidiabetic medication Takahiko Sakaue, Hiroya Terabe, Hidetoshi Takedatsu, Takumi Kawaguchi Hepatology Research.2024; 54(8): 729. CrossRef
Usefulness of health checkup‐based indices in identifying metabolic dysfunction‐associated steatotic liver disease Takao Miwa, Satoko Tajirika, Nanako Imamura, Miho Adachi, Ryo Horita, Tatsunori Hanai, Cheng Han Ng, Mohammad Shadab Siddiqui, Taku Fukao, Masahito Shimizu, Mayumi Yamamoto JGH Open.2024;[Epub] CrossRef
Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019 Pojsakorn Danpanichkul, Kanokphong Suparan, Priyata Dutta, Chuthathip Kaeosri, Banthoon Sukphutanan, Yanfang Pang, Narathorn Kulthamrongsri, Methasit Jaisa-aad, Cheng Han Ng, Margaret Teng, Masahito Nakano, Asahiro Morishita, Naim Alkhouri, Ju Dong Yang, Metabolism.2024; 158: 155958. CrossRef
Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi Clinical and Molecular Hepatology.2024; 30(3): 577. CrossRef
Are transmembrane 6 superfamily member 2 gene polymorphisms associated with steatohepatitis after pancreaticoduodenectomy? Tomotaka Mori, Eisuke Ozawa, Ryu Sasaki, Akane Shimakura, Kosuke Takahashi, Yoko Kido, Yasuko Kanda, Satoshi Matsuo, Kazuaki Tajima, Asami Beppu, Yasuhiko Nakao, Masanori Fukushima, Masafumi Haraguchi, Satoshi Miuma, Hisamitsu Miyaaki, Tomohiko Adachi, Su JGH Open.2024;[Epub] CrossRef
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi Clinical and Molecular Hepatology.2024; 30(4): 962. CrossRef
Recently, treatments for unresectable hepatocellular carcinoma (HCC) have undergone remarkable development. Various systemic chemotherapy drugs have been approved and are recommended by clinical guidelines worldwide. Although systemic treatments are effective and contribute to prolonged patient survival, their effects are unsatisfactory for some specific tumor conditions, such as macrovascular invasion. Hepatic arterial infusion chemotherapy (HAIC) is a traditional treatment for advanced HCC. As yet, there is no worldwide consensus recommending HAIC because no high-quality clinical trials have demonstrated its survival benefit. However, clinical evidence is gradually accumulating that shows its survival benefit, and it is recognized as an effective locoregional treatment for advanced HCC. Several HAIC regimens have been reported, including cisplatin monotherapy, cisplatin plus 5-fluorouracil (low-dose FP), lipiodol-suspended FP, and an oxaliplatin-based regimen. We have entered an era of chemo-diversity in the treatment of advanced HCC. This review aimed to clarify the relevance of HAIC in the era of chemo-diversity. We propose a multidisciplinary therapeutic strategy combining locoregional HAIC treatment with sequential drug therapy, with the aim of becoming cancer-free through conversion therapy.
Citations
Citations to this article as recorded by
Advances in transarterial chemoembolization for hepatocellular carcinoma: Integration with systemic therapies and emerging treatment strategies Henry Sutanto, Galih Januar Adytia, Elisa Elisa, Ummi Maimunah Cancer Pathogenesis and Therapy.2026; 4(1): 1. CrossRef
GLS1 inhibitor CB-839 inhibits the malignant progression of 5-FU resistant hepatoma cells by regulating glutamine metabolism Hao Wang, Xiao-yan Wang, Jian-bo Ji, Zong-xue Zheng, Peng-fei Shang, Xiu-li Guo Chemico-Biological Interactions.2026; 423: 111812. CrossRef
Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma with obstructive jaundice: A case report and review of literature Li Zhang, Pan Xiao, Lian-Dong Shi, Ke-Xin Chen, You-Fu Bing World Journal of Gastrointestinal Oncology.2026;[Epub] CrossRef
The risk and prognosis factors of second primary malignancies in hepatocellular carcinoma survivors Yi Fang, Bo Lao, Wenjia Fang Discover Oncology.2026;[Epub] CrossRef
Efficacy and Safety of HAIC-FOLFOX Plus Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-line Treatment for Unresectable Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis Peng Jiang, Chao Chen, Jing Tian, Fan Yang, Zhen-yu Jiang, An-xiang Hu, Bin Liu Academic Radiology.2025; 32(8): 4595. CrossRef
Advanced hepatocellular carcinoma treatment strategies: Are transarterial approaches leading the way? Stefan Patauner, Giovanni Scotton, Francesca Notte, Antonio Frena World Journal of Gastrointestinal Oncology.2025;[Epub] CrossRef
HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion Shuangyan Tang, Feng Shi, Yi Xiao, Hongjie Cai, Ping Ma, Yuanmin Zhou, Zhiqiang Wu, Song Chen, Wenbo Guo Hepatology International.2025; 19(1): 106. CrossRef
Community characteristics and relationship between gut microbiota and intratumoral microbiota in hepatocellular carcinoma Huangpeng Lin, Zexian Ma, Jin Li, Heping Zhu, Xuefeng Huang, Huimin Chen, Liang Tu, Yifan Lian, Yongjie Su Frontiers in Immunology.2025;[Epub] CrossRef
Efficacy and safety of neoadjuvant therapy for hepatocellular carcinoma with portal vein thrombosis: A meta‑analysis Wangyi Xuan, Xiaoming Zhang, Yingying Fang, Yueming Zhang, Zhiyi Xiang, Yifei Yu, Qingping Wu, Xingfen Zhang Oncology Letters.2025;[Epub] CrossRef
Anticipation for hepatic arterial infusion chemotherapy in the treatment of hepatocellular carcinoma Grigorios Christodoulidis, Dimitra Bartzi, Konstantinos E Koumarelas World Journal of Gastrointestinal Oncology.2025;[Epub] CrossRef
SERPINH1 secretion by cancer-associated fibroblasts promotes hepatocellular carcinoma malignancy through SENP3-mediated SP1/SQLE pathway Hua Xiao, Zhaoying Yao, Tao Li, Xin Fang, Xuejiao Xu, Sheng Hu, Ya Yang, Chenchen Jin, Yuxiang Fei, Chao Liu, Qianming Du International Immunopharmacology.2025; 150: 114259. CrossRef
Enhanced antitumor activity of combined hepatic arterial infusion chemotherapy with Lenvatinib and PD-1 inhibitors in unresectable hepatocellular carcinoma: a meta-analysis Lingling Zhao, Cheng Xu, Jiewen Deng, Yang Ni Frontiers in Oncology.2025;[Epub] CrossRef
Neoadjuvant therapy for hepatocellular carcinoma—priming precision innovations to transform HCC treatment Kristin E. Goodsell, Alice J. Tao, James O. Park Frontiers in Surgery.2025;[Epub] CrossRef
Adverse events associated with hepatic arterial infusion chemotherapy and its combination therapies in hepatocellular carcinoma: a systematic review Ying Wu, Zhenpeng Zeng, Shuanggang Chen, Danyang Zhou, Gangling Tong, Duanming Du Frontiers in Immunology.2025;[Epub] CrossRef
A Metrology Informatics Investigation of Conversion Therapy in Hepatocellular Carcinoma: 2014–2023 Qi-Feng Chen, Xiong-Ying Jiang, Min-Shan Chen, Ning Lyu, Ming Zhao Annals of Surgery Open.2025; 6(1): e562. CrossRef
Hepatic arterial infusion chemotherapy combined with lenvatinib and immune checkpoint inhibitor versus lenvatinib for advanced hepatocellular carcinoma: a multicenter study with propensity score and coarsened exact matching Qunfang Zhou, Hui Li, Ye Liang, Ruixia Li, Xiaohui Wang, Wei Wang, Mingyu Liu, Feng Duan, Zhimei Huang La radiologia medica.2025; 130(5): 662. CrossRef
Future perspectives on immunotherapy for hepatocellular carcinoma Landon L. Chan, Stephen L. Chan Therapeutic Advances in Medical Oncology.2025;[Epub] CrossRef
Novel multimodal analgesic regimen for perioperative pain management after hepatic artery infusion chemotherapy in patients with advanced hepatocellular carcinoma Jing Yan, Rui An, Jing-Jing Wang, Min Wang, Qi Zhao, Shen Zhao, Jian Xu World Journal of Gastrointestinal Surgery.2025;[Epub] CrossRef
Hepatic arterial infusion chemotherapy versus transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study Yi Zhang, Ze Zhang, Xiaoxv Yin, Anhui Xu, Yonghong Hao, Nan Jiang, Ruibing Zhou, Ketao Mu European Radiology.2025; 35(10): 6564. CrossRef
A network meta-analysis of different interventional treatment strategies for unresectable hepatocellular carcinoma Xing-Yan Le, Jun-Bang Feng, Xiao-Li Yu, Sui-Li Li, Xiaocai Zhang, Jiaqing Li, Chuan-Ming Li BMC Gastroenterology.2025;[Epub] CrossRef
Natural born Killers: Harnessing NK cells to treat cancer Kanchi Patell, Katherine Myers, Amr Mohamed, David Wald, J. Eva Selfridge Best Practice & Research Clinical Haematology.2025; 38(3): 101630. CrossRef
Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging Weihao Zhang, Xiaohui Zhao, Wei Gao, Tongguo Si, Qiang Zou, Xueling Yang, Wenge Xing, Haipeng Yu Frontiers in Immunology.2025;[Epub] CrossRef
Adjuvant chemotherapy improves post-transplant outcome in patients with hepatocellular carcinoma Heng-Kai Zhu, Hai-Bo Mou, Zhuo-Yi Wang, Wu Zhang, Dan Zhu, Si-Yi Zhong, Shu-Sen Zheng, Li Zhuang Hepatobiliary & Pancreatic Diseases International.2025; 24(5): 491. CrossRef
Predicting Resistance and Survival of HCC Patients Post-HAIC: Based on Shapley Additive exPlanations and Machine Learning Fan Yao, Jianliang Miao, Bing Quan, Jinghuan Li, Bei Tang, Shenxin Lu, Xin Yin Journal of Hepatocellular Carcinoma.2025; Volume 12: 1111. CrossRef
Transarterial chemoembolization combined with intra-arterial infusion of sintilimab and bevacizumab for advanced hepatocellular carcinoma: a phase 2 study Mao-Yuan Mu, Zi-Xiong Chen, Yu-Zhe Cao, Xiao-Bo Fu, Li-Jie Qiu, Han Qi, Fei Gao Cancer Letters.2025; 628: 217851. CrossRef
Comprehensive multi-omics analysis of bile acid metabolism in hepatocellular carcinoma: implications for prognosis, immune microenvironment, and therapeutic resistance Jiayan Ma, Ming Cheng, Limin Jin, Yong Wang, Zhengyang Feng, Yuntian Shen, Yaqun Zhu, Qiliang Peng Clinical and Translational Oncology.2025; 27(12): 4430. CrossRef
Establishment of a prognostic nomogram and risk stratification system for patients with distant-metastatic hepatocellular carcinoma: A population-based study Qiuhan Heng, Ying Leng, Gang Bai, Hua Yu Medicine.2025; 104(24): e42834. CrossRef
Combining Hepatic Arterial Interventional Therapies with Lenvatinib and Programmed Cell Death-1 Inhibitors for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Single-Center, Real-World Study Xuehan Shen, Tianyin Shao, Jun Yu, Zhiwei Zhang Journal of Hepatocellular Carcinoma.2025; Volume 12: 1267. CrossRef
Adjuvant Hepatic Arterial Infusion Chemotherapy Versus Transarterial Chemoembolization for Preventing Early Recurrence After Surgical Resection in Hepatocellular Carcinoma Yangshuo Xia, Wu Wen, Yangyu Liao, Yingxiao Cai, Renhua Wan Journal of Hepatocellular Carcinoma.2025; Volume 12: 1425. CrossRef
Senescent fibroblasts secrete CTHRC1 to promote cancer stemness in hepatocellular carcinoma Hai Huang, Wang Peng, Qiaodan Zhou, Yuchong Zhao, Luyao Liu, Haochen Cui, Jingwen Liang, Mengdie Cao, Wei Chen, Ronghua Wang, Shiru Chen, Si Xiong, Bin Cheng, Shuya Bai Cell Communication and Signaling.2025;[Epub] CrossRef
Conversion Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Retrospective Cohort Study Jienan Lu, Lusha Zhou, Shuai Zhang, Junxiu Li, Tanrong Liu, Bingying Huang Journal of Surgical Oncology.2025; 132(5): 917. CrossRef
Conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: A comparative analysis in a real-world cohort Yangyang Ou, Yiyu Chen, Kang Chen, Ming Yao, Guanglin Ling, Chun Liao, Yanlong Liu, Haizhao Cao, Jianjun Li, Chunming Wang, Yuanneng Nong, Ji'an Chen, Fei Huang, Yubin Huang, Xiaoyong Cai, Yihe Yan The American Journal of Surgery.2025; 250: 116602. CrossRef
Efficacy of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors (TKIs) in advanced hepatocellular carcinoma: a comparison with transarterial chemoembolization combined with TKIs Lei Fan, Lei Wang Acta Radiologica.2025; 66(12): 1311. CrossRef
Conversion Therapy Based on TACE/HAIC-Based Treatment to Improve the Therapeutic Effect of Initially Unresectable Hepatocellular Carcinoma Shuirong Lin, Zimin Song, Peizhe Chen, Xi Yu, Wenxuan Xie, Yunpeng Hua, Shaoqiang Li, Shunli Shen, Ming Kuang Liver Cancer.2025; : 1. CrossRef
PARK7-driven IGF2BP3–K76 lactylation mediates ferroptosis and HAIC resistance in hepatocellular carcinoma Zhiwen Zhu, Xinyu Xia, Yuanxiang Lu, Danfeng Li, Xincheng He, Baohua Zhang, Ge Xiong, Wanguang Zhang, Huifang Liang, Hong Zhu Redox Biology.2025; 87: 103869. CrossRef
FAIM modulates HCC progression via enhancing HMGA1 interaction with CDK7 and promoting its phosphorylation level Yuan Li, Wenna Liu, Xushen Fan, Xinyi Wu, Mingbo Cao, Xiuling Li, Amin Wurita, Suofeng Sun Journal of Translational Medicine.2025;[Epub] CrossRef
The interplay between hepatitis B virus and antitumor drugs in the treatment of hepatocellular carcinoma Tianyu Ma, Feilong Zhao, Linmei Yao, Chuanchun Mao, Yuan Tian, Youyou Ma, Fanyun Kong, Ruyu Liu Clinical and Experimental Medicine.2025;[Epub] CrossRef
Hepatic arterial infusion chemotherapy combined with lenvatinib and toripalimab for large hepatocellular carcinoma (> 10 cm) with major portal vein tumor thrombosis: a multicenter propensity score matching analysis Yangyang Li, Danchen Wang, Fengtao Zhang, Xiang Zheng, Yipei Song, Yang Ran, Xiangran Cai Frontiers in Immunology.2025;[Epub] CrossRef
Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma Yi-Min Zhang, Xin-Tong Wu, Jun-Zhe Yi, Jie Xu, Yu-Nan Zhang, Ning Lyu, Ming Zhao Liver Cancer.2025; 14(5): 620. CrossRef
Clinical efficacy of hepatic arterial infusion chemotherapy combined with transhepatic arterial embolization plus lenvatinib and tislelizumab or transarterial chemoembolization combined with lenvatinib plus tislelizumab in the treatment of advanced hepato Zha Peng, Yaqiong Wang, Boyu Chen, Zhuangrong Zhu, Chengyi He, Yang Wei, Hai Huang Frontiers in Oncology.2025;[Epub] CrossRef
Consensus Integration of Multiomics Data With Machine Learning Algorithms Reveals Heterogeneous Molecular Subtypes and Enables Personalized Treatment Strategies for Hepatocellular Carcinoma Zhipeng Jin, Kun Fang, Xue Zhang, Mengying Song, Hong Jiang, Yefu Liu, Sujit Nair Human Mutation.2025;[Epub] CrossRef
Hepatic arterial infusion chemotherapy via arterial infusion port combined with Atezolizumab and Bevacizumab for conversion therapy of advanced hepatocellular carcinoma: a case report Jiaxuan Liu, Zichun Zhao, Yulong Tian, Haibo Shao Discover Oncology.2025;[Epub] CrossRef
Conversion Therapy and Liver Regeneration in Liver Cancer Xiaoqin Wu Journal of Biosciences and Medicines.2025; 13(12): 374. CrossRef
Dual roles of USP1 in HELLS deubiquitination and SUMOylation drive EMT and FOLFOX-based chemoresistance Jie Gao, Nan Bai, Mingyu Liu, Ninghua Yao, Zhangzhi Tang, Banglong Xu, Weiting Chen, Xuyang He, Jiayu Shao, Saiyan Bian, Hui Zhao, Wenjie Zheng Oncogenesis.2025;[Epub] CrossRef
Mechanism study of oleanolic acid derivative, K73-03, inducing cell apoptosis in hepatocellular carcinoma Jiaqi Wang, Chuchu Ma, Zhongyuan Tang, Zhengwu Sun, Eskandar Qaed, Xinming Chi, Jun Wang, Yazeed Jamalat, Zhaohong Geng, Zeyao Tang, Qiying Yao Cancer Cell International.2024;[Epub] CrossRef
Efficacy and Safety of Hepatic Arterial Infusion Therapy with Cinobufacini in Advanced Hepatocellular Carcinoma with Macrovascular Invasion: A Retrospective Cohort Study Tao Xue, Hongbin Yu, Wenming Feng, Yao Wang, Shiyong Wu, Lili Wang, Peiqin Zhu, Jianming Guan, Quan Sun Cancer Management and Research.2024; Volume 16: 163. CrossRef
Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities Ming‐Da Wang, Xue‐Jun Xu, Ke‐Chun Wang, Yong‐Kang Diao, Jia‐Hao Xu, Li‐Hui Gu, Lan‐Qing Yao, Chao Li, Guo‐Yue Lv, Tian Yang Cancer Science.2024; 115(7): 2159. CrossRef
Higher objective responses by hepatic arterial infusion chemotherapy following atezolizumab and bevacizumab failure than when used as initial therapy in hepatocellular carcinoma: a retrospective study Jae-Sung Yoo, Ji Hoon Kim, Hee Sun Cho, Ji Won Han, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Suho Kim, Jung Suk Oh, Ho Jong Chun, Pil Soo Sung Abdominal Radiology.2024; 49(9): 3127. CrossRef
The Immune Inductive Role of Hepatic Arterial Infusion Chemotherapy Prior to Atezolizumab Plus Bevacizumab Combination Therapy in Hepatocellular Carcinoma Hiroyuki Suzuki, Miwa Sakai, Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Masahito Nakano, Tomotake Shirono, Yu Noda, Etsuko Moriyama, Ryoko Kuromatsu, Hironori Koga, Takumi Kawaguchi Gastro Hep Advances.2024; 3(4): 506. CrossRef
Consistent efficacy of hepatic artery infusion chemotherapy irrespective of PD‑L1 positivity in unresectable hepatocellular carcinoma Ji Kim, Young Kim, Hee-Chul Nam, Chang-Wook Kim, Jae-Sung Yoo, Ji Han, Jeong Jang, Jong Choi, Seung Yoon, Ho Jong Chun, Jung Oh, Suho Kim, Sung Lee, Pil Sung Oncology Letters.2024;[Epub] CrossRef
Combining liver-directed and immunotherapy in advanced hepatocellular carcinoma: A review and future directions Pranav Kumar, Chase J. Wehrle, Keyue Sun, Chunbao Jiao, Rebecca Panconesi, Mingyi Zhang, Noah X. Tocci, Hanna Hong, Abby Gross, Erlind Allkushi, Maureen Whitsett Linganna, Andrea Schlegel, Toms Augustin, Charles Miller, David CH Kwon, Kazunari Sasaki, Fed Surgical Oncology Insight.2024; 1(4): 100100. CrossRef
Advancing hepatocellular carcinoma treatment with hepatic arterial infusion chemotherapy Eda Caliskan Yildirim, Yakup Ergun World Journal of Gastrointestinal Oncology.2024; 16(12): 4757. CrossRef
Improved survival with second-line hepatic arterial infusion chemotherapy after atezolizumab-bevacizumab failure in hepatocellular carcinoma Ji Yeon Lee, Jaejun Lee, Suho Kim, Jae-sung Yoo, Ji Hoon Kim, Keungmo Yang, Ji Won Han, Jeong Won Jang, Jong Yong Choi, Seung Kew Yoon, Ho Jong Chun, Jung Suk Oh, Pil Soo Sung Frontiers in Oncology.2024;[Epub] CrossRef
Bavachin stimulates ferroptosis and reduces malignant phenotype progression of hepatocellular carcinoma cells by inducing lipid peroxidation by modulation of the Nrf2/HO-1 signaling pathway Haoyu Li American Journal of Translational Research.2024; 16(11): 6925. CrossRef
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi Clinical and Molecular Hepatology.2023; 29(2): 242. CrossRef
Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization Long-Wang Lin, Kun Ke, Le-Ye Yan, Rong Chen, Jing-Yao Huang Frontiers in Oncology.2023;[Epub] CrossRef
Case Report: Clinical application of continuous arterial infusion chemotherapy in neoadjuvant therapy for locally advanced gastric cancer Wenli Lin, Zhongxian Huang, Zhenhua Du, Yunshan Wang, Taiyang Zuo Frontiers in Oncology.2023;[Epub] CrossRef
Predictors of Survival in Patients With Hepatocellular Cancer Receiving Atezolizumab and Bevacizumab Matthew Ledenko, Lydia Mercado, Tushar Patel American Journal of Clinical Oncology.2024; 47(3): 105. CrossRef
Efficacy of Atezolizumab Plus Bevacizumab–Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma Etsuko Moriyama, Shigeo Shimose, Takashi Niizeki, Hideki Iwamoto, Masatoshi Tanaka, Tomotake Shirono, Yu Noda, Masahito Nakano, Ryoko Kuromatsu, Hironori Koga, Takumi Kawaguchi Current Oncology.2024; 31(10): 5821. CrossRef
Comment on “Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab” Binghua Li, Qiang Wang, Weiwei Hu, Huan Li, Peng Yan, Yajuan Cao, Decai Yu iLIVER.2024; 3(4): 100130. CrossRef
A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma Chih-Lang Lin, Kung-Hao Liang, Ching-Chih Hu, Cheng-Hung Chien, Li-Wei Chen, Rong-Nan Chien, Yang-Hsiang Lin, Chau-Ting Yeh International Journal of Molecular Sciences.2023; 24(2): 1681. CrossRef
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi Clinical and Molecular Hepatology.2023; 29(2): 242. CrossRef
Development and validation of prognostic nomograms for large hepatocellular carcinoma after HAIC Wang Yao, Ran Wei, Jia Jia, Wang Li, Mengxuan Zuo, Shuqing Zhuo, Ge Shi, Peihong Wu, Chao An Therapeutic Advances in Medical Oncology.2023;[Epub] CrossRef
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi Clinical and Molecular Hepatology.2023; 29(3): 593. CrossRef
Identifying risk factors of dose reduction or treatment discontinuation due to fatigue or gastrointestinal symptoms in patients receiving lenvatinib treatment for hepatocellular carcinoma Michio Kimura, Shiori Yamada, Makiko Go, Satoshi Yasuda, Hidenori Toyoda, Eiseki Usami Journal of Oncology Pharmacy Practice.2026; 32(1): 24. CrossRef
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease Mohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Ian Homer Cua, Chun-Jen Liu, Tawesak Tanwandee, Rino Gani, Wai-Kay Seto, Shahinul Alam, Dan Yock Young, Saeed Hamid, Ming-Hua Zheng, Takumi Kawaguchi, Wah-Kheong Chan, Diana Payawal, Soek-S Hepatology International.2025; 19(2): 261. CrossRef
The Impact of Rifaximin on Hepatic Encephalopathy during Lenvatinib Therapy in Patients with Hepatocellular Carcinoma and Splenorenal Shunt Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Tomotake Shirono, Etsuko Moriyama, Takumi Kawaguchi Internal Medicine.2025;[Epub] CrossRef
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives Yuhang Chen, Suoyi Dai, Chien-shan Cheng, Lianyu Chen Journal of Hematology & Oncology.2024;[Epub] CrossRef
The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea Yuri Cho, Bo Hyun Kim, Joong-Won Park Clinical and Molecular Hepatology.2023; 29(1): 99. CrossRef
Telephone follow‐up contributes to improving adherence and treatment duration in patients with hepatocellular carcinoma treated with lenvatinib Sayo Tsumura, Shigeo Shimose, Takashi Niizeki, Eri Kuboyama, Hideki Iwamoto, Masatoshi Tanaka, Etusko Moriyama, Tomotake Shirono, Kota Takaki, Yu Noda, Masahito Nakano, Mitsutoshi Inoue, Kazuki Tsustumi, Ryoko Kuromatsu, Hironori Koga, Kyoko Higuchi, Taku Journal of Gastroenterology and Hepatology.2023; 38(7): 1140. CrossRef
Correlation between branched-chain amino acids intake and total lymphocyte count in head and neck cancer patients: a cross-sectional study Yosua Yan Kristian, Rahmat Cahyanur, Yohannessa Wulandari, Wina Sinaga, Widjaja Lukito, Findy Prasetyawaty, Wiji Lestari BMC Nutrition.2023;[Epub] CrossRef
First
Prev
